Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

These clinical considerations provide information to healthcare professionals and public health officials on use of COVID-19 vaccines. They are informed by:

• Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC)
• COVID-19 vaccine approvalor Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA)
• CDC’s Emergency Use Instructions (EUI) for FDA-approved vaccines
• Emergency Use Listing (EUL) of COVID-19 vaccines by the World Health Organization (WHO)
• ACIP’s general best practice guidelines for immunization (GBPG)
• Expert opinion

The following COVID-19 vaccines, categorized into three vaccine types, are currently approved under a Biologics License Application (BLA) or authorized under an EUA by FDA (Table 1):

• mRNA vaccines
  • Moderna COVID-19 Vaccine/SPIKEVAX (1) and Moderna COVID-19 Vaccine, Bivalent
  • Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY (2) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent
• Protein subunit vaccine
  • Novavax COVID-19 Vaccine, Adjuvanted
• Adenovirus vector vaccine
  • Janssen (Johnson & Johnson) COVID-19 Vaccine

Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations (see Appendix A).

COVID-19 vaccine products (see Table 1) are formulated as follows:

• Monovalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2
• Bivalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2

None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines.

COVID-19 vaccine-specific FDA fact sheets and U.S. COVID-19 Vaccine Product Information can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.

Table 1. COVID-19 vaccine products currently approved or authorized in the United States*

Moderna

Novavax

Pfizer-BioNTech

Janssen

Groups recommended for vaccination

COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months.

CDC recommends that people stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent booster dose recommended for them by CDC (see Table 2 and Table 3).

See Appendices B (People who received COVID-19 vaccine outside the United States) and C (People who received COVID-19 vaccine as part of a clinical trial) for recommendations for these populations.

Primary series vaccination

For primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer-BioNTech.

Bivalent mRNA vaccines are not authorized at this time for primary series doses with the following exception: children ages 6 months–4 years who receive 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose.

Vaccine products made by the same manufacturer should be used for all doses of the primary series (see Interchangeability of COVID-19 vaccine products).

Booster vaccination

People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s) with the following exception: children ages 6 months–4 years who receive 2 primary series doses of a monovalent Pfizer-BioNTech vaccine and 1 bivalent Pfizer-BioNTech vaccine for the third primary series dose are not authorized to receive a booster dose at this time. Monovalent mRNA vaccines are not authorized as a booster dose.

A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Vaccine dosage and administration

In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination (Table 1) in accordance with the recommended intervals for that age group (3). However, for COVID-19 vaccination there are FDA-authorized exceptions (to the age-based product and dosage) for certain age transitions.

For guidance on vaccination in specific situations, see Transitioning from a younger to older age group, Considerations for extended intervals for COVID-19 vaccine primary series doses, and COVID-19 vaccination and SARS-CoV-2-infection.

Vaccine doses should be administered by the intramuscular route.

The COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is detailed below and summarized in Table 2.

Moderna COVID-19 Vaccine

• Children ages 6 months–4 years: A 2-dose primary series and 1 bivalent Moderna booster dose is recommended. The primary series doses are separated by 4–8 weeks and the bivalent booster dose is administered at least 2 months after completion of the primary series. Currently, only the bivalent Moderna booster dose is authorized for children in this age group who complete a Moderna primary series.
• Children age 5 years: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 4–8 weeks and the bivalent booster dose is administered at least 2 months after completion of the primary series.
• Children ages 6–11 years: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 4–8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series.

Pfizer-BioNTech COVID-19 Vaccine 

• Children ages 6 months–4 years: A 3-dose primary series is recommended. A monovalent vaccine is administered for the first and second doses, which are separated by 3–8 weeks. A bivalent vaccine is administered for the third primary series dose at least 8 weeks after the second monovalent primary series dose. Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who receive a bivalent Pfizer-BioNTech vaccine for the third primary series dose. Children in this age group who previously received 3 monovalent Pfizer-BioNTech primary series doses are authorized to receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the monovalent primary series.
• Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary series doses are separated by 3–8 weeks and the bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who complete a Pfizer-BioNTech primary series.
• Children ages 6–11 years: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 3-8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Moderna COVID-19 Vaccine

• People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 4–8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Novavax COVID-19 Vaccine

• People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 3–8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series.

Pfizer-BioNTech COVID-19 Vaccine

• People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 3–8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Use of the monovalent Novavax booster dose in limited situations

• People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Table 2. COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised

People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

See Appendix A for additional information on Janssen COVID-19 Vaccine.

An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these COVID-19 vaccines.

While absolute risk remains small, an elevated risk for myocarditis and pericarditis has been observed among mRNA COVID-19 vaccine recipients, particularly in males ages 12–39 years (see COVID-19 vaccination and myocarditis and pericarditis). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and through passive surveillance during post-authorization use outside the United States.

Some studies in adolescents (ages 12–17 years) and adults have shown the small risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness might be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit.

COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (i.e., Novavax and Pfizer-BioNTech) and 4-week (i.e., Moderna) interval between the first and second primary series doses. These intervals continue to be recommended for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about COVID-19 community levels or an individual’s higher risk for severe disease).

The COVID-19 vaccination schedule for people who are moderately or severely immunocompromised is detailed below and summarized in Table 3.

People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the booster dose.

Moderna COVID-19 Vaccine

• Children ages 6 months–4 years: A 3-dose primary series and 1 bivalent Moderna booster dose is recommended. The first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series. Currently, only the bivalent Moderna booster is authorized for children in this age group who complete a Moderna primary series.
• Children age 5 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series.
• Children ages 6–11 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series.

Pfizer-BioNTech COVID-19 Vaccine

• Children ages 6 months–4 years: A 3-dose primary series is recommended. A monovalent vaccine is administered for the first and second doses, which are separated by 3 weeks. A bivalent vaccine is administered for the third primary series dose at least 8 weeks after the second monovalent dose. Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who receive a bivalent Pfizer-BioNTech vaccine for the third primary series dose. Children in this age group who previously received 3 monovalent Pfizer-BioNTech primary series doses are authorized to receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the monovalent primary series.
• Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who complete a Pfizer-BioNTech primary series.
• Children ages 6–11 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Moderna COVID-19 Vaccine 

• People ages 12 years and older: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. For the primary series, the first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Novavax COVID-19 Vaccine

• People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 3 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series.

Pfizer-BioNTech COVID-19 Vaccine

• People ages 12 years and older: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

Use of the monovalent Novavax booster dose in limited situations

• People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Table 3. COVID-19 vaccination schedule for people who are moderately or severely immunocompromised

People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.

See Appendix A for additional information on Janssen COVID-19 Vaccine.

As of January 26, 2023, tixagevimab/cilgavimab (EVUSHELD™), a combination of two monoclonal antibodies, is not currently authorized for use in the United States. EVUSHELD™ was previously recommended for pre-exposure prophylaxis to supplement vaccine protection; however, SARS-CoV-2 variants currently circulating in the United States are resistant to EVUSHELD™.

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

• Active treatment for solid tumor and hematologic malignancies
• Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
• Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
• Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
• Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
• Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

For additional information about the degree of immune suppression associated with different medical conditions and treatments, providers can consult ACIP’s general best practices for vaccination of people with altered immunocompetence, the CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.

People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation.

Revaccination with Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine (regardless of vaccine administered for initial vaccination) should follow the recommended schedule and cannot exceed the number of primary series and booster doses currently authorized (Table 3). After revaccination with the primary series, the patient should receive 1 bivalent booster dose. Patients who received monovalent booster dose(s) prior to or during treatment should receive 1 bivalent mRNA booster dose as there is no revaccination for monovalent booster doses.

Recipients of HCT or CAR-T-cell therapy should undergo revaccination for the monovalent primary series and bivalent booster doses received prior to or during treatment. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.

Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine (primary series and bivalent booster doses) during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies). The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies.

A patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.

Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.

Timing of COVID-19 vaccination should take into consideration:

• Current or planned immunosuppressive therapies
• Optimization of both the patient’s medical condition and anticipated response to vaccination
• Individual benefits and risks

On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised. However, providers should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance.

The utility of serologic testing, cellular immune testing, or B-cell quantification to assess immune response to vaccination and guide clinical care has not been established. Such testing outside of the context of research studies is not recommended at this time.

Doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered valid. This applies to primary series and booster doses. If a dose is administered prior to the 4-day grace period, see Appendix D. Doses administered at any time after the recommended interval are valid.

In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination (Table 1). If a person moves from a younger age group to an older age group during the primary series or between the primary series and the booster dose, they should receive the vaccine product and dosage for the older age group for all subsequent doses with the following exception: FDA EUA requires that children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the primary series must complete the series they start.

FDA authorization allows for dosing options for certain other situations when a child ages from a younger to older age group for Moderna and Pfizer-BioNTech COVID-19 vaccines.

In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit. However, there are additional considerations if administering an orthopoxvirus vaccine (see below).

Extensive experience with non-COVID 19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone. Studies that compared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these vaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity; no specific safety concerns were identified.

Orthopoxvirus vaccination

• People who previously received a dose of any COVID-19 vaccine may be given orthopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations.
• People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or young adult males, might consider waiting 4 weeks before receiving a dose of any COVID-19 vaccine because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the unknown risk for myocarditis and pericarditis after JYNNEOS administration.

For best practices for administering multiple injections, see ACIP’s general best practices and Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book).

Primary series

All COVID-19 vaccine primary series doses should be from the same manufacturer. A mixed primary series composed of any combination of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines is not authorized.

In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose (no Vaccine Adverse Event Reporting System [VAERS] report is required):

• Same vaccine not available
• Previous dose unknown
• Person would otherwise not complete the primary series.
• Person starts but unable to complete a primary series with the same COVID-19 vaccine due to a contraindication

The same monovalent vaccine product should be used for all doses in the primary series with the following exception: children ages 6 months–4 years who received 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose.

Children ages 6 months–4 years who received 1 monovalent Moderna vaccine and 1 monovalent Pfizer-BioNTech vaccine for the first 2 doses of a primary series should follow a 3-dose schedule. A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the 3-dose primary series.

People who received Janssen COVID-19 Vaccine after a dose of another COVID-19 vaccine should be considered to have received a valid, single-dose Janssen primary series.

Booster vaccination

For booster vaccination, bivalent mRNA vaccines are recommended. Any homologous (i.e., same manufacturer for the primary series and booster dose) or heterologous (i.e., different manufacturer for the primary series and booster dose) bivalent mRNA vaccine can be used as authorized by FDA for a given age group and product (see COVID vaccination schedules for People who are not moderately or severely immunocompromised and People who are moderately or severely immunocompromised).

For people who receive a mixed primary series, booster recommendations are as follows:

• Children ages 6 months–4 years:
  • Who receive a mixed 3-dose primary series with any combination of monovalent Moderna and monovalent Pfizer-BioNTech vaccines should receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the primary series.
  • Who receive a mixed 3-dose primary series with a bivalent Pfizer-BioNTech vaccine as the third primary series dose should receive 1 bivalent Pfizer-BioNTech booster dose when they turn age 5 years and at least 2 months after completion of the primary series.
• Children age 5 years who receive a mixed primary series should receive 1 bivalent Pfizer-BioNTech vaccine booster dose at least 2 months after completion of the primary series.
• People ages 6 years and older who receive a mixed primary series should receive 1 mRNA booster dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the mixed monovalent primary series.

More information on the interchangeability of COVID-19 vaccine products for children and adolescents can be here.

Pre-vaccination testing

Antibody testing is not currently recommended to assess the need for vaccination in an unvaccinated person or to assess immunity to SARS-CoV-2 following COVID-19 vaccination. If antibody testing was done, vaccination with the primary series or a booster dose should be completed as recommended regardless of the antibody test result.

Interpretation of SARS-CoV-2 test results in vaccinated people

Prior receipt of a COVID-19 vaccine will not affect the results of SARS-CoV-2 viral tests (nucleic acid amplification or antigen tests).

See also CDC COVID-19 health care professional, CDC COVID-19 laboratory, and FDA SARS-CoV-2 laboratory testing Web pages.

Providers should counsel COVID-19 vaccine recipients, parents, or guardians about expected local and systemic reactions.

• Local reactions include pain/tenderness, swelling, and erythema at the injection site.
• Systemic reactions include fever, fatigue/malaise, headache, chills, myalgia, arthralgia; among younger children, particularly those younger than ages 3 years, systemic reactions also can include irritability/crying, sleepiness, and loss of appetite.
• Antipyretic or analgesic medications can be taken for the treatment of post-vaccination local or systemic symptoms but should not be used prophylactically for prevention of post-vaccination symptoms. In general, aspirin is not recommended for use in children and adolescents ages 17 years and younger as an antipyretic or analgesic due to the risk of Reye’s syndrome.

Localized axillary lymphadenopathy on the same side as the vaccinated arm or groin, if vaccination was in the thigh, has been observed following vaccination with Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines (4). Infrequently, people who have received dermal fillers might experience temporary swelling at or near the site of filler injection (usually face or lips) following a dose of an mRNA COVID-19 vaccine.

Unless people have a contraindication to vaccination, they should be encouraged to complete the series to optimize protection against COVID-19 even if they experience local or systemic symptoms following the first dose.

Myocarditis and pericarditis: People receiving any COVID-19 vaccine, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following COVID-19 vaccination. Counseling should include the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination, particularly in the week after vaccination. See COVID-19 vaccination and myocarditis and pericarditis for additional information and Appendix A for information on Janssen COVID-19 Vaccine.

Anaphylactic reactions: Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. Administration of antihistamines before COVID-19 vaccination to prevent allergic reactions is not generally recommended. However, while antihistamines will not prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients who might be at higher risk for allergic reactions. For more information on the assessment and potential management of anaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination.

For more information on patient counseling, see Vaccine Recipient Education.

Syncope (fainting) might occur in association with any injectable vaccine, especially in adolescents. In accordance with GBPG, vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes after vaccination.

Additionally, providers should consider observing people with the following medical histories for 30 minutes after COVID-19 vaccination to monitor for allergic reactions:

• Allergy-related contraindication to a different type of COVID-19 vaccine
• Non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine
• Anaphylaxis after non-COVID-19 vaccines or injectable therapies

See also Contraindications and precautions.

CDC considers COVID-19 vaccination to be contraindicated or a precaution in certain situations (see Table 4).

Table 4. Contraindications and precautions to COVID-19 vaccination

For information on contraindications and precautions to Janssen COVID-19 vaccination, see Appendix A.

Healthcare professionals and health departments may request a consultation from the Clinical Immunization Safety Assessment COVIDvax project for a complex COVID-19 vaccine safety question not readily addressed by CDC guidance.

Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS. Vaccination providers are required by FDA and the provider agreement for the CDC COVID-19 Vaccination Program to report the following that occur after COVID-19 vaccination under BLA or EUA:

• Vaccine administration errors whether or not associated with an adverse event
• Serious adverse events, irrespective of attribution to vaccination
• Cases of Multisystem Inflammatory Syndrome (MIS) in adults and children
• Cases of myocarditis
• Cases of pericarditis
• Cases of COVID-19 that result in hospitalization or death

Reporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused the event. Information on how to submit a report to VAERS is available at https://vaers.hhs.gov or by calling 1-800-822-7967.

In addition, CDC has developed a new voluntary, smartphone-based tool, v-safe, to provide near real-time health check-ins after patients receive COVID-19 vaccination.

In clinical trials of Moderna and Pfizer-BioNTech COVID-19 vaccines, types of post-vaccination reactions were generally similar. The most frequent reported reactions, by age group, follow below.

Older children, adolescents, and adults

• Local: Pain at the injection site, sometimes severe
• Systemic: Fatigue, headache, and myalgia

Overall, symptoms tended to be more frequent and severe following the second dose of vaccine and among adolescents and younger adults compared with older adults.

Younger children (ages 6 months–4 years [Pfizer-BioNTech] or 6 months–5 years [Moderna])

• Local: Pain/tenderness at the injection site
• Systemic: Fatigue; in the youngest children (ages 6–23 months), irritability/crying and drowsiness/sleepiness

In all age groups, most systemic symptoms were mild to moderate in severity, typically began 1–2 days after vaccination, and resolved after 1–2 days.

Febrile seizures can occur in infants and young children ages 6 months–5 years with any condition that causes a fever (most common with high fevers), including COVID-19. Febrile seizures are uncommon after vaccination and were rare in mRNA COVID-19 vaccine clinical trials for infants and young children. In rare instances, administration of certain combination vaccines or more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in infants and young children. The impact of coadministration of COVID-19 and routine vaccines on the risk of febrile seizures has not been specifically studied. CDC is monitoring for febrile seizures following COVID-19 vaccination in infants and young children.

See also COVID-19 vaccination and myocarditis and pericarditis and Vaccine reactions and adverse events for Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines.

In clinical trials of Novavax COVID-19 Vaccine, the most frequent reported vaccine reactions included:

• Local reactions: Pain/tenderness, redness, and swelling at the injection site
• Systemic symptoms: Fatigue/malaise, headache, and muscle pain

Most symptoms were mild to moderate in severity and resolved within 1–3 days. Overall, symptoms were more frequent in people ages 12–64 years compared to people ages 65 years and older and more frequent after dose 2 than dose 1 of the primary series. Among adults ages 18 years and older who received the Novavax booster dose, symptoms were more frequently reported after the booster dose than dose 2 of the primary series.

See also COVID-19 vaccination and myocarditis and pericarditis and Vaccine reactions and adverse events for Novavax COVID-19 Vaccine.

Cases of myocarditis and pericarditis have rarely been observed following receipt of COVID-19 vaccines used in the United States. Evidence from multiple monitoring systems in the United States and globally support a causal association for mRNA COVID-19 vaccines (Moderna or Pfizer-BioNTech) and myocarditis and pericarditis. Data from clinical trials of Novavax COVID-19 Vaccine and global vaccine safety monitoring systems suggest an increased risk of myocarditis and pericarditis following Novavax vaccination. Data from post-authorization monitoring of Janssen COVID-19 Vaccine suggest a possible increased risk of myocarditis and pericarditis following Janssen vaccination.

For mRNA COVID-19 vaccines and Novavax COVID-19 Vaccine:

• After reviewing available data on the risks and benefits (see mRNA COVID-19 vaccines and Novavax COVID-19 Vaccine), ACIP and CDC determined that the benefits (e.g., prevention of COVID-19 and its severe outcomes) outweigh the rare risk of myocarditis and pericarditis in all populations recommended for vaccination.
• Extending the interval to 8 weeks between the first and second primary series doses for some people might reduce the rare risk of vaccine-associated myocarditis and pericarditis (see Considerations for extended intervals for COVID-19 vaccine primary series doses).
• People, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following receipt of these vaccines and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19, including the possibility of cardiac sequelae.
  • Counseling should include the need to seek care if symptoms of myocarditis or pericarditis, such as chest pain, shortness of breath, or tachycardia develop after vaccination, particularly in the week after vaccination.
  • In younger children, symptoms of myocarditis might also include non-specific symptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy.

For information on myocarditis or pericarditis following receipt of Janssen COVID-19 Vaccine, see Appendix A.

Myocarditis or pericarditis after a dose of COVID-19 vaccine

Development of myocarditis or pericarditis after a dose of any COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine, and subsequent doses should generally be avoided. Until additional safety data are available, experts advise that these people should:

• Generally not receive a subsequent dose of any COVID-19 vaccine
• If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, wait until at least after their episode of myocarditis or pericarditis has resolved (i.e., resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by patient’s clinical team)

Considerations for subsequent COVID-19 vaccination might include:

• Myocarditis or pericarditis considered unrelated to vaccination (e.g., due to SARS-CoV-2 or other viruses), especially if the diagnosis of myocarditis or pericarditis occurred more than 3 weeks after the most recent dose of COVID-19 vaccine
• Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)
• Timing of any immunomodulatory therapies; ACIP’s general best practice guidelines for immunization can be consulted for more information

Safety monitoring is ongoing to further assess the known and potential risks for myocarditis and pericarditis after COVID-19 vaccination in all age groups. CDC is also assessing the long-term effects of myocarditis in people with myocarditis after COVID-19 vaccination.

For myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.

History of myocarditis or pericarditis prior to COVID-19 vaccination

People who have a history of myocarditis or pericarditis unrelated to COVID-19 vaccination (e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved (i.e., resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by the person’s clinical team). For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.

History of other heart disease

People who have a history of other heart disease, including congenital heart disease and Kawasaki disease, may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine.

Adolescents and young adults

• Cases of myocarditis and pericarditis have rarely occurred after mRNA COVID-19 vaccines. Cases have occurred most frequently in adolescent and young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (i.e., Moderna and Pfizer-BioNTech); however, cases have also been observed after dose 1 and booster doses.
• The reporting rates for myocarditis after mRNA COVID-19 primary series vaccination or booster vaccination exceed the background rates in several age groups in males and females with the highest rates observed in males ages 12–39 years; see the June 23, 2022and September 1, 2022 ACIP meetings for more information.
• Based on the overall data to date, the risk for myocarditis and pericarditis after an mRNA COVID-19 booster dose in adolescents and young adults appears generally similar to or lower than the risk after a second mRNA COVID-19 vaccine primary series dose.
• In age groups where product comparisons can be made (i.e., 18–39 years), some evidencesuggests that the risk of myocarditis and pericarditis might be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech COVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems.

Children

• In post-authorization surveillance, cases of myocarditis and pericarditis among children ages 5–11 years after Pfizer-BioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of myocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male children in this age group.
• No cases of myocarditis or pericarditis were reported in children in the pre-authorization clinical trials of Pfizer-BioNTech (ages 6 months–4 years) or Moderna (ages 6 months–5 years) vaccines.
• To date, post-authorization surveillancehas not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (i.e., Pfizer-BioNTech) and ages 6 months–5 years (i.e., Moderna).

Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been reported during post-authorization use outside the United States. These findings suggest that an increased risk for these conditions might be present after receiving Novavax COVID-19 vaccine.

Recent exposure to SARS-CoV-2 is not a contraindication or precaution to COVID-19 vaccination. People with a known or potential SARS-CoV-2 exposure can receive vaccine if they do not have symptoms consistent with SARS-CoV-2 infection; however, people should follow CDC’s post-exposure guidance.

COVID-19 vaccines are not recommended for post-exposure prophylaxis. People should be informed that vaccination is to help prevent severe COVID-19 following future exposures.

COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2 infection. This includes people with prolonged post-COVID-19 symptoms and applies to primary series and booster doses.

People with known current SARS-CoV-2 infection should defer any COVID-19 vaccination, including booster vaccination, at least until recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.

In addition, people who recently had SARS-CoV-2 infection may consider delaying a primary series dose or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic). Studies have shown that increased time between infection and vaccination might result in an improved immune response to vaccination. Also, a low risk of reinfection has been observed in the weeks to months following infection. Individual factors such as risk of COVID-19 severe disease, COVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection.

Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for the purpose of vaccine decision-making.

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation. Those who received antibody products due to a recent SARS-CoV-2 infection should follow the guidance in the section above.

MIS-C is a rare but severe condition in children and adolescents infected with SARS-CoV-2. MIS-A, a similar condition in adults, is even rarer and less well characterized. Both include a dysregulated immune response to SARS-CoV-2 infection. There are limited data on the safety of COVID-19 vaccines in people who have had MIS-C or MIS-A (MIS C/A). The risk of recurrence of a dysregulated immune response following reinfection with SARS-CoV-2 or an MIS-like illness following COVID-19 vaccination is unknown.

People with a history of MIS-C or MIS-A

Experts consider the benefits of COVID-19 vaccination for people with a history of MIS-C/A (i.e., a reduced risk of severe disease including potential recurrence of MIS-C after reinfection) to outweigh a theoretical risk of an MIS-like illness or the risk of myocarditis following COVID-19 vaccination for those who meet the following two criteria:

1. Clinical recovery has been achieved, including return to baseline cardiac function; and
2. It has been at least 90 days after the diagnosis of MIS-C/A

COVID-19 vaccination may also be considered for people who had MIS-C/A and do not meet both criteria, at the discretion of their clinical care team (see Consultation for decisions about COVID-19 vaccination). Experts view clinical recovery, including return to baseline cardiac function, as an important factor when considering COVID-19 vaccination. Additional factors, such as the risk of severe COVID-19 due to age or certain medical conditions, may also be considered.

Timing of COVID-19 vaccination

Initiation of COVID-19 vaccination in people with a history of MIS-C/A should take into consideration current or planned immunomodulatory therapies for treatment of MIS-C/A (see Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies).

Evaluation of people who develop MIS-C or MIS-A after COVID-19 vaccination

In the rare instance a person develops MIS-C, MIS-A, or a similar clinical illness after receipt of COVID-19 vaccine, referral to a specialist in infectious diseases, rheumatology, and/or cardiology should be considered.

• Assessment should include testing for current or prior SARS-CoV-2 infection, in addition to other potential etiologies as clinically indicated.
• Obtaining a serum sample before any intravenous immune globulin (IVIG) is administered is highly recommended so that the sample can be tested for SARS-CoV-2 anti-nucleocapsid antibody, which might require a reference laboratory.
  • A positive anti-nucleocapsid antibody test result indicates prior SARS-CoV-2 infection. (To test for current SARS-CoV-2 infection, a molecular diagnostic or antigen test should be used).
  • Anti-spike protein antibody testing cannot be used to determine SARS-CoV-2 infection status in a vaccinated person because a positive test result can be induced by either COVID-19 vaccination or SARS-CoV-2 infection.
• Treatment should not be delayed until test results are available.

Decisions about administration of subsequent COVID-19 vaccine doses in people who develop MIS-C or MIS-A after COVID-19 vaccination depend on timing of MIS in relation to vaccination, clinical recovery, and epidemiologic considerations.

Administration of subsequent COVID-19 vaccine doses: Onset of MIS 90 days or more after most recent COVID-19 vaccine dose

Administration of subsequent COVID-19 vaccine dose(s) should be considered for those who meet the two criteria listed below:

1. Clinical recovery has been achieved, including return to baseline cardiac function; and
2. It has been at least 90 days after the diagnosis of MIS-C/A

For people who had MIS-C/A but do not meet both criteria above, see Consultation for decisions about COVID-19 vaccination.

Administration of subsequent COVID-19 vaccine doses: Onset of MIS fewer than 90 days after most recent COVID-19 vaccine dose

Subsequent COVID-19 vaccine dose(s) should be deferred at this time until additional data are available. However, on a case-by-case basis, a provider may offer subsequent dose(s) if the two criteria above are met and there is strong evidence that the MIS-C/A was a complication of a recent SARS-CoV-2 infection.

A conversation between the patient and/or their guardian(s) and their clinical team or a specialist (e.g., infectious diseases, rheumatology, and/or cardiology) is strongly encouraged to assist with decisions about the use of COVID-19 vaccines in the setting of MIS-C or MIS-A.

For complicated situations, not addressed by the guidance above, healthcare and public health professionals may consider requesting a consultation from the Clinical Immunization Safety Assessment COVIDvax project. An illness consistent with MIS-C or MIS-A after receiving COVID-19 vaccine should be reported to VAERS.

Staying up to date with COVID-19 vaccinations is recommended for people who are pregnant, trying to get pregnant now, or who might become pregnant in the future, and people who are breastfeeding. A growing body of evidence on the safety and effectiveness of COVID-19 vaccination indicates that the benefits of vaccination outweigh any potential risks of COVID-19 vaccination during pregnancy.

Side effects can occur after COVID-19 vaccination in pregnant people, similar to those among non-pregnant people. Acetaminophen can be offered as an option for pregnant people experiencing fever (fever has been associated with adverse pregnancy outcomes) or other post-vaccination symptoms.

1. SPIKEVAX is the proprietary name for the product licensed under the BLA. The Moderna COVID-19 Vaccine has been available since December 18, 2020 under an EUA. The Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and older (supplied in multiple-dose vials with red caps and labels with light blue borders) has the same formulation as SPIKEVAX. The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the emergency use authorized Moderna COVID-19 Vaccine for people ages 12 years and older (supplied in multiple-dose vials with red caps and labels with light blue borders) have the same formulation and can be used interchangeably to provide primary series doses to individuals 12 years of age and older without presenting any safety or effectiveness concerns.
2. COMIRNATY is the proprietary name for the product licensed under the BLA. The Pfizer-BioNTech COVID-19 Vaccine has been available since December 10, 2020 under an EUA. The two approved formulations of COMIRNATY and the two FDA-authorized formulations of the Pfizer-BioNTech COVID-19 Vaccine for people ages 12 years and older are the same formulations, and vials of the BLA-compliant vaccine might bear the name “Pfizer-BioNTech COVID-19 Vaccine.” The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the emergency use authorized formulations of Pfizer-BioNTech COVID-19 Vaccine for people ages 12 years and older (gray cap/label vials), when prepared according to their respective instructions for use, can be used interchangeably without presenting any safety or effectiveness concerns.
3. For intervals of 3 months or less, 28 days (4 weeks) is a “month.” For intervals of 4 months or longer, a month is a “calendar month.”  For age group ranges (e.g., 6 months–4 years, 5–11 years), a dash (–) should be read as “through” and the upper range includes that year through the last day before the birth date.
4. The Society of Breast Imaging has developed Revised SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination which includes considerations for patients and healthcare professionals in scheduling screening exams in relation to the administration of a COVID-19 vaccine.